The drugs, sutezolid and delpazolid, have demonstrated strong antimicrobial activity and a notably better safety profile ...

A five-item tool using spirometry and basic clinical data may predict recurrent tuberculosis with moderate accuracy, helping ...

The drugs, sutezolid and delpazolid, have demonstrated strong antimicrobial activity and a notably better safety profile compared to linezolid, with potential to replace this current cornerstone in ...

Two international clinical studies led by PD Dr Norbert Heinrich at the Institute of Infectious Diseases and Tropical Medicine at LMU University Hospital Munich with international partners have shown ...

The centerpiece of the acquisition is Ohtuvayre, a treatment for chronic obstructive pulmonary disease that secured U.S. approval last year. The drug’s commercial launch has exceeded Wall Street ...

“Silicosis is caused by inhaling air that contains silica particles, which over time creates scar tissue in the lungs, ...

China labor compliance amid extreme heat is increasingly regulated. Learn how foreign companies can meet legal obligations in ...

Tuberculosis bacteria rely on a family of genes that help them survive the challenging journey from one person's lungs to ...

"What's new is getting those results in homes, during real use." Researchers make game-changing discovery that could fix ...

Targeted Oncology connects oncology professionals with updates on immunotherapy, biomarkers, cancer pathways, and targeted ...

The drugmaker will provide, at no profit, doses to treat up to 2 million people in resource-limited countries. Meanwhile, Arvinas' John Houston is retiring from his role leading the biotech.